William Blair Predicts Ikena Oncology FY2029 Earnings

Key Points

• William Blair predicts Ikena Oncology will report an estimated fiscal year 2029 earnings per share (EPS) of ($5.41), significantly lower than the current consensus estimate of ($0.91).
• Wedbush has downgraded Ikena Oncology's price target from $25.00 to $23.00 and issued a "neutral" rating for the stock.
• Insider transactions indicate strong confidence, with Director David P. Bonita purchasing 83,611 shares and Director Otello Stampacchia buying 267,556 shares, both at an average price of $29.90 per share.

Ikena Oncology, Inc. (NASDAQ:IMA - Free Report) - Investment analysts at William Blair issued their FY2029 earnings per share estimates for shares of Ikena Oncology in a report issued on Wednesday, July 30th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($5.41) for the year. The consensus estimate for Ikena Oncology's current full-year earnings is ($0.91) per share.

Separately, Wedbush reduced their price target on Ikena Oncology from $25.00 to $23.00 and set a "neutral" rating for the company in a report on Friday, July 25th.

Ikena Oncology Trading Down 4.5%

IMA traded down $0.75 during trading on Friday, reaching $15.85. The stock had a trading volume of 15,706 shares, compared to its average volume of 14,357. The stock's 50 day moving average is $16.03 and its two-hundred day moving average is $15.76. The company has a market capitalization of $63.72 million, a price-to-earnings ratio of -2.06 and a beta of 0.51. Ikena Oncology has a one year low of $11.65 and a one year high of $23.28.

Ikena Oncology (NASDAQ:IMA - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Ikena Oncology by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock worth $98,000 after purchasing an additional 29,369 shares in the last quarter. Aldebaran Capital LLC purchased a new position in shares of Ikena Oncology in the first quarter valued at approximately $317,000. XTX Topco Ltd lifted its position in shares of Ikena Oncology by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock valued at $72,000 after acquiring an additional 43,924 shares in the last quarter. BML Capital Management LLC lifted its position in shares of Ikena Oncology by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock valued at $4,750,000 after acquiring an additional 124,937 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Ikena Oncology in the fourth quarter valued at approximately $72,000. 75.00% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director David P. Bonita bought 83,611 shares of the business's stock in a transaction dated Friday, July 25th. The shares were purchased at an average price of $29.90 per share, with a total value of $2,499,968.90. Following the transaction, the director owned 287,885 shares in the company, valued at $8,607,761.50. This trade represents a 40.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Otello Stampacchia bought 267,556 shares of the stock in a transaction on Friday, July 25th. The stock was purchased at an average price of $29.90 per share, with a total value of $7,999,924.40. Following the completion of the acquisition, the director directly owned 454,982 shares in the company, valued at approximately $13,603,961.80. This trade represents a 142.75% increase in their position. The disclosure for this purchase can be found here. Insiders own 5.94% of the company's stock.

Ikena Oncology Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.